Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Hepatocellular carcinoma (HCC) is a primary liver malignancy arising from hepatocytes and is the 5th most common cancer and 2nd leading cause of cancer death globally, with approximately 900,000 new cases annually. In the US, approximately 42,000 new cases are diagnosed each year. HCC arises predominantly on a background of chronic liver disease or cirrhosis in over 90% of cases. The BCLC staging system guides treatment allocation and reflects the dual impact of liver function and tumor burden. Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

Chronic hepatitis B virus (HBV) is the dominant global risk factor, accounting for approximately 50% of HCC cases worldwide; HBsAg carriers have a 100-fold increased risk. Chronic HCV cirrhosis causes approximately 25% of HCC globally. NAFLD and NASH cirrhosis are the fastest-growing risk factors in Western countries, driven by obesity and type 2 diabetes. Alcohol-related cirrhosis, aflatoxin B1 exposure (poorly stored grains in sub-Saharan Africa and Asia), hereditary hemochromatosis, alpha-1 antitrypsin deficiency, and primary biliary cirrhosis are additional causes. The causes of Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

Most HCC cases are asymptomatic in early stages, detected on biannual surveillance ultrasound in cirrhotic patients. Symptomatic disease presents with right upper quadrant pain, unintentional weight loss, fatigue, anorexia, and hepatomegaly. Jaundice, ascites, and variceal bleeding indicate decompensated liver disease. Paraneoplastic syndromes include hypoglycemia (insulin-like growth factor secretion), erythrocytosis, hypercalcemia, and diarrhea. Tumor rupture causes acute abdomen with hemoperitoneum. AFP is elevated greater than 400 ng/mL in approximately 20% of cases. Symptoms of Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

Dynamic CT or MRI using LI-RADS criteria is diagnostic for HCC greater than or equal to 10 mm in cirrhotic livers: arterial phase hyperenhancement with portal venous or delayed phase washout appearance (LI-RADS 5) requires no biopsy. AFP and AFP-L3 fraction supplement imaging. Biopsy is reserved for atypical imaging features. BCLC staging integrates tumor number and size, Child-Pugh liver function score, performance status, and vascular invasion. Biannual liver ultrasound plus AFP surveillance is recommended for all cirrhotic patients and chronic HBV carriers. Diagnosis of Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

BCLC 0 (very early, single HCC up to 2 cm): ablation (RFA or MWA) achieves near-100% local control. BCLC A (early): surgical resection (for preserved liver function), liver transplant (Milan criteria), or ablation. BCLC B (intermediate, no vascular invasion): TACE or DEB-TACE. BCLC C (advanced, vascular invasion or extrahepatic spread): atezolizumab plus bevacizumab (IMbrave150, first-line preferred); durvalumab plus tremelimumab (HIMALAYA, first-line alternative); sorafenib or lenvatinib (second-choice first-line); cabozantinib, ramucirumab (AFP greater than 400), regorafenib (second-line). BCLC D: best supportive care. Treatment of Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year survival rates by treatment: surgical resection 50-70%, liver transplant (Milan criteria) 70-75%, ablation (BCLC 0/A) 40-70% at 5 years, TACE (BCLC B) median OS 20-26 months, systemic therapy (BCLC C) median OS 19.2 months with atezolizumab plus bevacizumab. Effective antiviral therapy for HBV reduces HCC recurrence after curative treatment by approximately 40-50%. Overall 5-year survival for all HCC patients combined is approximately 20%, reflecting late-stage diagnosis in most cases. The prognosis for Hepatocellular Carcinoma (HCC): Causes, BCLC Staging, and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

HBV vaccination is the most effective HCC prevention, reducing HBV-related HCC incidence in vaccinated populations. HBV antiviral therapy (tenofovir, entecavir) and HCV direct-acting antivirals achieving SVR reduce HCC risk by 50-70% in treated patients. Weight management, alcohol cessation, and diabetes control reduce NAFLD-related cirrhosis progression. Aflatoxin B1 exposure is minimized by proper grain storage and fumonisin biomarkers. Biannual liver ultrasound plus AFP surveillance is recommended for all cirrhotic patients and chronic HBV carriers to detect HCC at a potentially curative stage.

Go to the ER immediately for sudden severe right upper quadrant pain with haemodynamic instability in a cirrhotic patient (HCC rupture with hemoperitoneum), acute hepatic encephalopathy, or variceal haemorrhage. See a hepatologist or oncologist urgently for new right upper quadrant pain, unexplained weight loss, or jaundice in a known cirrhotic patient; AFP greater than 400 ng/mL or a rapidly rising AFP trend; or a LI-RADS 4 or 5 liver lesion on any imaging. A missed biannual surveillance ultrasound interval should be rescheduled immediately. Proactive surveillance: all cirrhotic patients regardless of aetiology and all chronic HBV carriers (HBsAg-positive) — including those without established cirrhosis — must enrol in biannual liver ultrasound with or without AFP screening.